Tumor DepositsNCT06884839
Tumor Deposits in Colorectal Cancer and Its Prognostic Value in Survival and Metastasis
An observational study of Tumor Deposits and Colorectal Cancer, run by Minia University at 1 site in Egypt.
Trial summary
This study aims to evaluate the tumor deposits in colorectal cancer and its prognostic value in survival and metastasis Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Tumor Deposits, Colorectal Cancer, Prognosis
- What is being tested?
- Therapeutic resection
- Type of treatment
- Surgery or procedure
- How many people
- 30 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Apr 2022to 1 Apr 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This prospective and retrospective study will be conducted on 30 patients with colorectal cancer.
Who may be able to join
- Age above 18 years old.
- Both sexes.
- All Colorectal cancer patients From Stage I to III Colorectal cancer with pathologically positive Tumor deposits.
Who cannot join
- Patient took neoadjuvant therapy.
- No information available on tumor deposits.
- Colorectal cancer is not the only primary cancer.
- Patients with incomplete information about follow-up.
Trial locations and contacts
1 site in 1 country.
About this study
This study aims to evaluate the tumor deposits in colorectal cancer and its prognostic value in survival and metastasis
Read the detailed description
Tumor deposits (TDs) are defined as isolated tumor foci found in the pericolonic or perirectal fat or the adjacent mesentery (mesocolonic fat) away from the invasive margin of the tumor without evidence of residual lymphatic tissue. TDs are significantly correlated with poor prognosis after colorectal cancer surgery.
- Conditions
- Tumor Deposits, Colorectal Cancer, Prognosis, Survival, Metastasis
- Being tested
- Therapeutic resection
- Medical subject headings
- Extranodal Extension, Colorectal Neoplasms, Neoplasm Metastasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Therapeutic resectionProcedure or surgery
Patients with colorectal cancer underwent therapeutic resection with pathologically positive tumor deposits (TDs) to determine distant metastasis occurrence and the effect of TDs on survival.
| Study group | Role | What they receive |
|---|---|---|
| Therapeutic resection group | Patients with colorectal cancer underwent therapeutic resection with pathologically positive tumor deposits (TDs) to determine distant metastasis occurrence and the effect of TDs on survival. Receives: Procedure: Therapeutic resection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Patients' overall survival
Patients' overall survival (OS) is defined as from colorectal cancer (CRC) diagnosis to death.
Measured: 2 years postoperatively
Secondary outcomes (1)
Distant metastasis
Distant metastasis is defined as the presence of liver, lung, bone, or brain metastases during or after colorectal cancer (CRC) diagnosis.
Measured: 2 years postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Mar 2025
- Study start1 Apr 2022
- Primary completion1 Apr 2023
- Study completion1 Apr 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Tumor DepositsStudies of the same condition, open and under way.
- More trials run by Minia UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Minia University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Abdelrahman Mohamed Salah, Minia University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06884839
- Sponsor's protocol ID
- 1267/09/2024
- Status last verified
- May 2026
- First submitted
- 13 Mar 2025
- Last updated
- 27 May 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Study at a glance
From the registry record, last updated by the sponsor on 27 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Tumor Deposits in Colorectal Cancer and Its Prognostic Value in Survival and Metastasis
- ClinicalTrials.gov ID
- NCT06884839
- Acronym / sponsor ID
- 1267/09/2024
- Conditions
- Tumor Deposits, Colorectal Cancer, Prognosis, Survival, Metastasis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Minia UniversityUniversity, hospital or other
- Study start
- 1 Apr 2022 (actual)
- Primary completion
- 1 Apr 2023 (actual)
- Study completion
- 1 Apr 2025 (actual)
- First posted
- 19 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the tumor deposits in colorectal cancer and its prognostic value in survival and metastasis
Detailed description
Tumor deposits (TDs) are defined as isolated tumor foci found in the pericolonic or perirectal fat or the adjacent mesentery (mesocolonic fat) away from the invasive margin of the tumor without evidence of residual lymphatic tissue. TDs are significantly correlated with poor prognosis after colorectal cancer surgery.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Therapeutic resection group | – | Procedure: Therapeutic resectionPatients with colorectal cancer underwent therapeutic resection with pathologically positive tumor deposits (TDs) to determine distant metastasis occurrence and the effect of TDs on survival. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This prospective and retrospective study will be conducted on 30 patients with colorectal cancer.
Key inclusion criteria (3 listed)
- Age above 18 years old.
- Both sexes.
- All Colorectal cancer patients From Stage I to III Colorectal cancer with pathologically positive Tumor deposits.
Key exclusion criteria (4 listed)
- Patient took neoadjuvant therapy.
- No information available on tumor deposits.
- Colorectal cancer is not the only primary cancer.
- Patients with incomplete information about follow-up.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Therapeutic resectionPatients with colorectal cancer underwent therapeutic resection with pathologically positive tumor deposits (TDs) to determine distant metastasis occurrence and the effect of TDs on survival. | Procedure or surgery | Therapeutic resection group |
Primary outcome
Patients' overall survival
Time frame: 2 years postoperatively
Patients' overall survival (OS) is defined as from colorectal cancer (CRC) diagnosis to death.
1 secondary outcome
Distant metastasis
Time frame: 2 years postoperatively
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 May 2026.
- Individual participant dataSharing planned: Yes. The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Related trials for Tumor Deposits
Active, not recruitingPhase 3
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Light Chain Deposition Disease, Smoldering Multiple Myeloma
RecruitingObservational study
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
Multiple Myeloma, Amyloidosis
Active, not recruiting
Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery
Hepatocellular Carcinoma, Neuroendocrine Tumors
Recruiting
A Novel Ureteric Stent in Kidney Stone Patients and Oncology Patients Compared to a Conventional JJ Stent
Catheter Blockage, Oncology
Not yet recruitingObservational study
Reporting of Tumour Deposits in Colorectal Cancer by Radiology and Pathology
Rectal Adenocarcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Tumor Deposits and Colorectal Cancer, run by Minia University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patients' overall survival (time frame: 2 years postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 May 2026.